India's largest drugmaker Sun Pharmaceutical Industries reported a 59 percent plunge in second-quarter profit on Tuesday, hurt by generics pricing pressure in the United States.
The company had posted a net profit of Rs 2,235.14 crore for the corresponding period of the previous fiscal, Sun Pharmaceutical Industries said in a BSE filing.
EBITDA (earnings before interest, tax, depreciation and amortisation) is likely to fall 57 percent to Rs 1,357.4 crore and margin may shrink 1830 basis points to 20 percent YoY.
"A challenging U.S. generic pricing environment coupled with continued investments in building our global speciality business has impacted our Q2 performance". "We expect our performance to gradually improve in the second half of this year", Sun Pharma's Managing Director Dilip Shanghvi said in a statement. Domestic sales grew 11 per cent to Rs 2,221 crore. US sales for the quarter fell 44 percent to $309 million while sales from India rose 11 percent.
Taro Pharma, which contributes 16 percent to total sales and over 30 percent of total EBITDA, reported a 57.6 percent fall year-on-year in profit at Dollars 52.4 million for July-September quarter.
Credit Suisse Charged by New York State Department
The state said Credit Suisse predicted that the algorithm would generate about $2 million in profits in 2013. In late September, the British bank HSBC agreed to pay $175 million to avoid prosecution.
Total War Saga: Thrones of Britannia announced for 2018
SEGA has officially announced the first entry in its Total War spin-off series , which pits the Vikings against Great Britain. The series , which focuses on specific periods in history, will have " Thrones of Britannia " as its first entry.
Tesla factory is a 'hotbed for racist behavior': suit
According to the early reports, Tesla's semi truck would clock between 200 and 300 miles, and it is intended for day trips. Tesla has roughly 33,000 employees globally but has never publicly released its diversity statistics, Bloomberg reported.